Atea Pharmaceuticals, Inc.

NASDAQ:AVIR

Biotechnology

Healthcare
$3.99 -0.81%

-$0.04 today

Market cap
$320.41M
Beta
0.32
P/E (TTM)
-2.0
EPS (TTM)
-$2.14
52W Low $2.78High $6.45

Volume 0.34M

Average 0.34M

AVIR Investing Cash Flow

Net cash used in or generated by investments in assets, acquisitions, and securities.

Atea Pharmaceuticals, Inc.NASDAQ: AVIR

Investing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Investing cash flow dips below year-ago levels

Q1 FY2026 investing cash flow of $29.74M fell 65.3% year over year, behind the +56.5% change in trailing-twelve-month investing cash flow. Sequentially, it fell 36.2% from the prior quarter.

Context

  • Investing cash flow increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -65.3% toward the trailing-twelve-month pace of +56.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$29.74M-36.2% QoQ
Last fiscal yearDec 2025
$188.79M+236.5% YoY
LTMMar 2026
$132.92M+56.5% YoY
Investing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-65.3%——
1 year+236.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Investing Cash Flow history

USD · from the cash flow

Latest · FY2025
188.79M USD
Year-over-year change
+236.5%

Investing Cash Flow vs competitors

How AVIR compares with its peers on the latest reported figures

  • AVIR's LTM Mar 2026 investing cash flow of $132.92M is the 2nd largest of the 5 companies compared; the peer median is $26.56M.
  • Its year-over-year change of +56.5% is the highest of 5, against a peer median of -124.3%.
AVIR Competitors Peer median
Investing Cash Flow for AVIR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VIRVir Biotechnology, Inc.LTM Mar 2026$195.39M -67.3%—298.3%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$132.92M +56.5%——
ASMBAssembly Biosciences, Inc.LTM Mar 2026$125.44M -525.4%—176.4%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$59.54M -177.1%-9.8%86.0%
ABUSArbutus Biopharma CorporationLTM Mar 2026$6.43M -71.6%—3.4%
Peer median (excluding AVIR) $26.56M-124.3%-9.8%131.2%

Competitors are the stored peer set for AVIR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income121.19M(115.91M)(135.96M)(168.39M)(158.35M)
Depreciation & Amortization29K260K416K416K416K
Deferred Income Tax(29.39M)0(48.56M)0(6.36M)
Stock-Based Compensation39.62M46.72M49.43M51.77M20.72M
Change in Working Capital(247.85M)(46.59M)16.16M(7.48M)16.48M
Accounts Receivables00000
Inventory00000
Accounts Payables10.29M(1.98M)1.7M206K8.49M
Other Working Capital(258.13M)(44.6M)14.46M(7.68M)8M
Other Non-Cash Items29.39M(5.47M)33.11M(11.82M)(4.94M)
Operating Cash Flow(87.01M)(120.98M)(85.4M)(135.5M)(132.03M)
Capital Expenditures(4K)(1.94M)000
Acquisitions (Net)0453.47K000
Purchases of Investments0(545.35M)(562.36M)(461.18M)(281.94M)
Sales of Investments091.89M602.67M517.28M470.73M
Other Investing Activities0(453.47K)000
Investing Cash Flow(4K)(455.41M)40.3M56.11M188.79M
Debt Repayment00000
Common Stock Issued1.47M230K257K267K259K
Common Stock Repurchased0000(25.52M)
Dividends Paid00000
Other Financing Activities0140K00(485K)
Financing Cash Flow1.47M370K257K267K(25.75M)
Effect of Forex Changes00000
Net Change in Cash(85.54M)(576.02M)(44.84M)(79.13M)31.02M
Free Cash Flow(87.01M)(122.93M)(85.4M)(135.5M)(132.03M)

Atea Pharmaceuticals, Inc.

NASDAQ:AVIR

Intrinsic Alpha fair value

Locked

Current Price

$3.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.